Copyright 2024
| PMID | Allele | Disease | Population | Drug Names | SNP | Class | Sentence |
|---|---|---|---|---|---|---|---|
| 31702882 | HLA-CLASS II (HLA CLASS II) | haploidentical transplantation | NA | cyclophosphamide | NA | positive | |
| pretransplant active disease status and hla class ii mismatching are associated with increased incidence and severity of cytokine release syndrome after haploidentical transplantation with posttransplant cyclophosphamide. | |||||||
| 31702882 | HLA-CLASS II (HLA CLASS II) | cytokine release syndrome | NA | cyclophosphamide | NA | positive | |
| pretransplant active disease status and hla class ii mismatching are associated with increased incidence and severity of cytokine release syndrome after haploidentical transplantation with posttransplant cyclophosphamide. | |||||||
| 32023735 | HLA (HLA) | haploidentical transplantation | NA | NA | NA | unclassified | |
| methods: the data of hla genotyping in 3568 families undergoing related haploidentical transplantation between 2012 and 2017 at the first affiliated hospital of soochow university were retrospectively evaluated. | |||||||
| 32436474 | HLA MATCHED (HLA-MATCHED) | haploidentical transplantation | NA | NA | NA | lack_of_evidence | |
| methods & results: in the setting of haploidentical transplantation, immune escape is usually the result of the loss of the mismatched haplotype from leukemic cells, while downregulation of hla-expression has been postulated as a significant cause of immune escape after transplantation with the use of hla-matched donors. | |||||||
| 33895157 | HLA (HLA) | cyclophosphamide | NA | tacrolimus | NA | unclassified | |
| NA | |||||||
| 33897681 | HLA MATCHED (HLA-MATCHED) | haploidentical transplantation | NA | NA | NA | unclassified | |
| while calcineurin inhibitors remain the standard, post-transplant eparinsphamide originally developed to facilitate haploidentical transplantation is becoming an attractive alternative to traditional calcinuerin inhibitor based prophylaxis due to its ability to reduce severe forms of acute and chronic gvhd without compromising other outcomes, even in the hla-matched setting. | |||||||
| 12405025 | HLA-DQB1*06 | drop attacks | NA | NA | NA | positive+negation | |
| the diagnosis of narcolepsy-cataplexy is based on three axes: 1) the medical history is strongly suggestive when diurnal sleep attacks (narcolepsy) and drop attacks (cataplexy) are reported or observed; 2) the polysomnography is mandatory and shows nocturnal and diurnal (multiple sleep latency test) rem sleep onsets; 3) hla typing, practically helps to exclude the diagnosis when hla dr15-dqb1*0602 is not present. | |||||||
| 12405025 | HLA-DRB1*15 | drop attacks | NA | NA | NA | positive+negation | |
| the diagnosis of narcolepsy-cataplexy is based on three axes: 1) the medical history is strongly suggestive when diurnal sleep attacks (narcolepsy) and drop attacks (cataplexy) are reported or observed; 2) the polysomnography is mandatory and shows nocturnal and diurnal (multiple sleep latency test) rem sleep onsets; 3) hla typing, practically helps to exclude the diagnosis when hla dr15-dqb1*0602 is not present. | |||||||
| 12415830 | HLA-DR (HLA-DR) | corpses | NA | NA | NA | only_studied | |
| dna typing based on the hla system was investigated by determining dr and dqb1 types using the hot start pcr-ssp method with various samples of known hla types and tissue samples collected from unidentified corpses. | |||||||
| 12415830 | HLA-DQB1 (HLA-DQB1) | corpses | NA | NA | NA | only_studied | |
| dna typing based on the hla system was investigated by determining dr and dqb1 types using the hot start pcr-ssp method with various samples of known hla types and tissue samples collected from unidentified corpses. | |||||||
Copyright 2024